Gallwitz 2012

NCT00622284

1 Treatments

**Studied treatment**  
linagliptin (5 mg once daily) add-on therapy to preferably > 1500 mg metformin

**Control treatment**  
glimepiride (1—4 mg) orally once daily add-on therapy to preferably > 1500 mg metformin

**Concomittant treatments**  
-

2 Patients

**Patients**  
Type 2 diabetes mellitus with insufficient glycaemic control with metformin

**Inclusion criteria**  
1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone or with metformin and one other oral antidiabetic drug  
2. HbA1c 6.0 - 9.0% at screening for patients treated with metformin and one other oral antidiabetic drug  
3. HbA1c 6.5 - 10.0% at screening for patients treated with metformin alone  
4. HbA1c 6.5 10.0% at beginning of the placebo run-in phase

**Exclusion criteria**  
1. Myocardial infarction, stroke or TIA  
2. Impaired hepatic function  
3. Renal failure or renal impairment  
4. Treatment with rosiglitazone or pioglitazone within 6 months prior to screening  
5. Treatment with insulin or GLP-1 analogue/antagonists within 3 months prior to screening

3 Methods

**Blinding**  
double-blind

**Design**  
Parallel groups

**Centers**  
-

**Geographical area**  
USA

**Sizes**  
777/775
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>MI</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>stroke</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause deaths</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>nephropathy</td>
<td>-/777</td>
<td>-/775</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References